August 2026: Charlie’s Holdings Reports 116% Revenue Growth, FDA Non-Enforcement Inclusion for 30 SKUs, and Key Commercial Initiatives
For the second quarter ended June 30, 2026, Charlie’s Holdings (CHUC) reported total revenue of $3.8 million, representing a 116% increase compared to $1.8 million in Q2 2025. This top-line expansion was primarily driven by higher sales of nicotine-based products and non-nicotine alternatives, notably significant sales growth from its SBX disposable vapor line. Gross profit rose 130% year-over-year to $1.1 million, with gross margins expanding to 29.4% from 27.6% in the prior-year period. Total operating expenses reached $2.4 million, up 63% from $1.4 million in Q2 2025, yielding an operating loss of $1.2 million compared to $1.0 million in Q2 2025. As of June 30, 2026, the company held $0.5 million in cash, total assets of $12.8 million, and shareholders’ equity of $3.1 million. Insiders demonstrated confidence during the first half of 2026 by purchasing $270,000 in common stock (1,350,000 restricted shares at $0.20 per share) with no warrants or inducements.
FDA Non-Enforcement Guidelines and the 30 PACHA SKUs
A central regulatory milestone highlighted in the release was the FDA’s notification to Charlie’s on June 23, 2026. The FDA tentatively identified 30 SKUs of the company’s PACHA product line—all of which have submitted Premarket Tobacco Product Applications (PMTAs)—for inclusion on the FDA’s public-facing webpage of products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements.
Management characterized this notification as a highly promising development that strengthens the company’s market positioning. Management emphasized that while the U.S. market continues to be impacted by non-compliant, illicit foreign products, Charlie’s remains focused on strict regulatory compliance, quality product engineering, and flavor innovation. This non-enforcement recognition aligns with broader industry shifts noted by the company, including recent FDA market authorizations for non-tobacco flavored ENDS products.
Commercial Plans and Strategic Rollouts
Charlie’s outlined several core commercial growth drivers aimed at expanding market share and retail footprint:
Age-Gated Flavored Disposable Launch: The company is preparing for what management considers the single most critical initiative in Charlie’s history—the rollout of America’s first age-gated flavored disposable vape. The company plans to initiate test-marketing across hundreds of compliance-oriented retail stores, a strategic move that management believes carries substantial regulatory upside and could positioned the firm for significant long-term market capitalization growth.
State-Level Approvals & SBX Expansion: Charlie’s launched its SBX 25K Virginia Tobacco disposable line across California after obtaining California Unflavored Tobacco List (UTL) authorization for four modern disposable devices.
Next-Generation Device Introductions: The company launched its high-capacity 75K disposables featuring upgraded triple mesh coil technology, refined ergonomics, increased puff capacity, and a menu of ten distinct flavors designed for adult consumers.
